The Market For Protein-Protein Interactions: Technologies With Tremendous Growth Potential
by Anonymous

ARLINGTON, VA – February 1, 2002 – Within the next 12 months the percentage of scientists who will likely be using protein microarray technology is projected to increase five-fold, according to a recent market research survey of scientists actively engaged in protein research. Similarly, a three-fold increase in percentage of scientists who will likely be using microfluidics lab-on-a-chip technology within the next year is also forecasted.

These findings are from an eight-part market research series, “The Tools & Techniques of Protein Science: Catalyzing the Future of Proteomics,” which details all aspects of the protein research market. The separate reports, which can be purchased individually or as a set, were recently published by BioInformatics LLC, a leading provider of market research to the biotechnology industry. The eight reports are based on questionnaires that were fielded to qualified members of The Science Advisory Board (http://www.scienceboard.net) - the world’s largest online panel of scientific customers.

According to Tamara Zemlo PhD, Director of Scientific & Medical Communications for The Science Advisory Board, “Protein-protein interactions constitute an essential aspect of the normal workings of the living cell and unraveling the various interactions in which proteins are involved is an invaluable way of understanding innate protein function.” As a result, BioInformatics’ series has two reports that focus on these interactions, “Biomolecular Interactions (In Vivo Methods)” and “Biomolecular Interactions (In Vitro Methods).” Zemlo says, “The in vivo study of protein biomolecular interactions is critical because the function of an isolated protein and the function of that protein in the complex cellular environment are likely to be quite different. Traditionally, complementary in vitro methods required sample amounts, analysis conditions and time scales that are incompatible with investigations in biological systems. With cutting-edge in vitro technologies, such as microarrays and microfluidic-based tools, these limitations can now be overcome.”

Invitrogen, Clontech, Promega and Stratagene have distinguished themselves among suppliers of products and/or technologies for studying protein interactions in vivo. Additionally, the early adopters of protein microarrays surveyed note Ciphergen Biosystems, Packard Bioscience and Biacore as the companies they most often associate with products and/or instrumentation for this technology. Such industry leaders are looking to the data in these reports and others in the series to assess their market position, create more effective marketing strategies and develop new products precisely tailored to the needs of the marketplace.

For example, findings show that the major factor in influencing a researcher’s decision to use an in vivo system for studying protein-protein interactions over another is its ability to simultaneously detect/analyze multiple sets of protein-protein interactions in a single screening. Additionally, “faster analysis time” is the major factor in influencing a scientist’s decision to embrace microarrays, while “increased precision and accuracy” is the most important factor in the decision to use microfluidics lab-on-a-chip technology.

ABOUT BIOINFORMATICS LLC

BioInformatics LLC (http://www.gene2drug.com) is a market research firm located in Arlington, Virginia. BioInformatics supports marketing, sales and R&D executives in the life science, medical device and pharmaceutical industries through published research reports, custom research and consulting. BioInformatics sponsors The Science Advisory Board (http://www.scienceboard.net), an online panel of more than 6,000 scientists, physicians and other biomedical customers from 62 countries who participate in surveys that address emerging technologies, test customer reactions to new product concepts, measure brand awareness and assess advertising effectiveness.

FOR A COMPLIMENTARY EXECUTIVE SUMMARY PLEASE VISIT HTTP://WWW.GENE2DRUG.COM OR CONTACT:

Alyssa Martin
BioInformatics LLC
2111 Wilson Blvd. Suite 1200
Arlington, VA 22201
703.525.3872 x358 phone
703.522.3685 fax
a.martin@gene2drug.com
http://www.gene2drug.com




This article courtesy of http://www.allwheyprotein.com. You may freely reprint this article on your website or in your newsletter provided this courtesy notice and the author name and URL remain intact.

Submit Your Article